Search results for " THERAPY"

showing 10 items of 9467 documents

Peripheral artery disease, redox signaling, oxidative stress – Basic and clinical aspects

2017

Reactive oxygen and nitrogen species (ROS and RNS, e.g. H2O2, nitric oxide) confer redox regulation of essential cellular signaling pathways such as cell differentiation, proliferation, migration and apoptosis. At higher concentrations, ROS and RNS lead to oxidative stress and oxidative damage of biomolecules (e.g. via formation of peroxynitrite, fenton chemistry). Peripheral artery disease (PAD) is characterized by severe ischemic conditions in the periphery leading to intermittent claudication and critical limb ischemia (end stage). It is well known that redox biology and oxidative stress play an important role in this setting. We here discuss the major pathways of oxidative stress and re…

0301 basic medicineAntioxidantRedox signalingmedicine.medical_treatmentCellular differentiationClinical BiochemistryReview Article030204 cardiovascular system & hematologyPharmacologymedicine.disease_causeBiochemistrychemistry.chemical_compound0302 clinical medicineGene Regulatory Networks610 Medicine & healthlcsh:QH301-705.5chemistry.chemical_classificationlcsh:R5-920Anticholesteremic AgentsReactive Nitrogen Speciesmedicine.symptomlcsh:Medicine (General)Oxidation-ReductionPeroxynitriteSignal Transductionmedicine.medical_specialtyCell signalingAntioxidant therapy610 Medicine & healthNitric oxide03 medical and health sciencesPeripheral Arterial DiseasemedicineHumansExerciseReactive oxygen speciesbusiness.industryOrganic ChemistryClaudication and critical limb ischemiaWalking distanceIntermittent claudicationSurgeryOxidative Stress030104 developmental biologychemistrylcsh:Biology (General)Peripheral artery (occlusive) diseasebusinessReactive Oxygen SpeciesOxidative stressRedox Biology
researchProduct

AMG900 as novel inhibitor of the translationally controlled tumor protein

2020

Abstract Introduction Cancer is one of the leading causes of death worldwide. Classical cytotoxic chemotherapy exerts high side effects and low tumor selectivity. Translationally controlled tumor protein (TCTP) is a target for differentiation therapy, a promising, new therapeutic approach, which is expected to be more selective and less toxic than cytotoxic chemotherapy. The aim of the present investigation was to identify novel TCTP inhibitors. Methods We performed in silico screening and molecular docking using a chemical library of more than 31,000 compounds to identify a novel inhibitor of TCTP. We tested AMG900 in vitro for binding to TCTP by microscale thermophoresis and co-immunoprec…

0301 basic medicineApoptosisCell Cycle ProteinsToxicologyResting Phase Cell CycleFlow cytometry03 medical and health sciences0302 clinical medicineCyclin D1Differentiation therapyCell Line TumorNeoplasmsTranslationally-controlled tumor proteinBiomarkers TumormedicineHumansCyclin D3medicine.diagnostic_testbiologyChemistryG1 PhaseTumor Protein Translationally-Controlled 1General MedicineMolecular Docking SimulationBlot030104 developmental biologyProtein Biosynthesis030220 oncology & carcinogenesisCancer cellMCF-7 CellsCancer researchbiology.proteinPhthalazinesCyclin-dependent kinase 6Chemico-Biological Interactions
researchProduct

The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

2017

Mucopolysaccharidosis (MPS) VI is an autosomal recessive lysosomal storage disorder arising from deficient activity of N-acetylgalactosamine-4-sulfatase (arylsulfatase B) and subsequent intracellular accumulation of the glycosaminoglycans (GAGs) dermatan sulfate and chondroitin-4-sulfate. Manifestations are multi-systemic and include skeletal abnormalities such as dysostosis multiplex and short stature. Reference height-for-age growth charts for treatment-naive MPS VI patients have been published for both the slowly and rapidly progressing populations. Categorization of disease progression for these charts was based on urinary GAG (uGAG) level; high (>200μg/mg creatinine) levels identified …

0301 basic medicineArylsulfatase BMaleLysosomal storage disorderN-Acetylgalactosamine-4-SulfataseEndocrinology Diabetes and MetabolismMucopolysaccharidosisGrowthBiochemistryGastroenterologychemistry.chemical_compoundEndocrinologyChildMucopolysaccharidosis VIAge FactorsMucopolysaccharidosis VIEnzyme replacement therapyRecombinant ProteinsDiabetes and MetabolismEnzyme replacement therapy; Galsulfase; Growth; Height; Lysosomal storage disorder; Maroteaux-Lamy syndrome; Mucopolysaccharidosis; Mucopolysaccharidosis VI; Endocrinology Diabetes and Metabolism; Biochemistry; Molecular Biology; Genetics; EndocrinologyChild PreschoolFemalemedicine.symptommedicine.medical_specialtyAdolescentUrinary systemShort stature03 medical and health sciencesGalsulfaseInternal medicineGeneticsmedicineHumansEnzyme Replacement TherapyMolecular BiologyCreatinineHeightbusiness.industryInfant NewbornInfantmedicine.diseaseBody HeightMucopolysaccharidosisMaroteaux–Lamy syndrome030104 developmental biologychemistryImmunologyMaroteaux-Lamy syndromebusinessFollow-Up StudiesMolecular genetics and metabolism
researchProduct

The European regulatory environment of rna-based vaccines

2016

A variety of different mRNA-based drugs are currently in development. This became possible, since major breakthroughs in RNA research during the last decades allowed impressive improvements of translation, stability and delivery of mRNA. This article focuses on antigen-encoding RNA-based vaccines that are either directed against tumors or pathogens. mRNA-encoded vaccines are developed both for preventive or therapeutic purposes. Most mRNA-based vaccines are directly administered to patients. Alternatively, primary autologous cells from cancer patients are modified ex vivo by the use of mRNA and then are adoptively transferred to patients. In the EU no regulatory guidelines presently exist t…

0301 basic medicineAutologous cellMessenger RNAVaccinesAnticancer vaccinationGenetically modified medicinal productsbusiness.industryGenetic enhancementmRNARNAGenetic therapy03 medical and health sciences030104 developmental biology0302 clinical medicineAntigenPreventive and therapeutic approachesInfectious disease (medical specialty)030220 oncology & carcinogenesisAdvanced therapy medicinal products (ATMP)ImmunologyMedicineVaccination against infectious diseasebusinessRegulatory framework in the EUEx vivo
researchProduct

Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

2018

PubMed: 29599078

0301 basic medicineBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences.HBsAgPediatricsDelphi TechniqueInfectious Disease TransmissionCHRONIC HBV INFECTION ; NATURAL-HISTORY ; FOLLOW-UP ; HBSAG ; CARRIERS ; AGE ; COUNTRIES ; DISEASE ; ANTIGEN ; COHORTddc:616.07Global Healthmedicine.disease_causeDISEASE0302 clinical medicinePrevalenceHBVChildddc:616Antiviral Agents/therapeutic useeducation.field_of_studyBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti.Chronic/drug therapy/epidemiology/prevention & control/transmissionGastroenterologyHepatitis B Surface Antigens/bloodHepatitis BCARRIERSHepatitis B10219 Clinic for Gastroenterology and HepatologyChild Preschool030211 gastroenterology & hepatologyViral hepatitisViral loadCOUNTRIESAdultmedicine.medical_specialtyHepatitis B vaccineANTIGENPopulation610 Medicine & healthAntiviral AgentsMass VaccinationHepatology; Gastroenterology03 medical and health sciencesHepatitis B ChronicHBSAGAGESDG 3 - Good Health and Well-beingmedicineHumansCOHORT2715 GastroenterologyPreschooleducationDisease burdenHepatitis B virusHepatitis B Surface AntigensHepatologybusiness.industryViral VaccinesNATURAL-HISTORYmedicine.diseaseInfectious Disease Transmission VerticalCHRONIC HBV INFECTIONVertical/prevention & control030104 developmental biology2721 HepatologyHuman medicineFOLLOW-UPbusiness
researchProduct

Dietary polyphenols for managing cancers: What have we ignored?

2020

Abstract Although the chemoprevention and anti-cancer activities of dietary polyphenols have been evidenced through both in vitro and in vivo studies, most of the human clinical trials were unsuccessful or even harmful. Debates on the beneficial roles of dietary polyphenols in cancer therapy are increasing. Many dietary polyphenols studies are conducted by in vitro experiments, but the nature of these studies does not consider the complexity of metabolic processes that are present in vivo. These can often cause instability in the dietary polyphenols, thereby leading to unsuccessful extrapolation into animal or human studies. Dietary polyphenols often have low bioavailability, which is mainl…

0301 basic medicineBioavailabilityCancer therapyMetabolitePharmacology03 medical and health sciences0302 clinical medicineAnti-cancer activityIn vivoMedicineTherapeutic windowCellular metabolismHuman studiesbusiness.industryMicrobiotafood and beveragesDietary polyphenolBioavailability030104 developmental biologyPolyphenol030220 oncology & carcinogenesisCancer cellbusinessStabilityFood ScienceBiotechnology
researchProduct

Targeting distinct myeloid cell populations in vivo using polymers, liposomes and microbubbles

2016

Identifying intended or accidental cellular targets for drug delivery systems is highly relevant for evaluating therapeutic and toxic effects. However, limited knowledge exists on the distribution of nano- and micrometer-sized carrier systems at the cellular level in different organs. We hypothesized that clinically relevant carrier materials, differing in composition and size, are able to target distinct myeloid cell subsets that control inflammatory processes, such as macrophages, neutrophils, monocytes and dendritic cells. Therefore, we analyzed the biodistribution and in vivo cellular uptake of intravenously injected poly(N-(2-hydroxypropyl) methacrylamide) polymers, PEGylated liposomes…

0301 basic medicineBiodistributionMyeloidPolymersCellBiophysicsMice NudeCapsulesBioengineeringSpleen02 engineering and technologyFlow cytometryBiomaterialsMice03 medical and health sciencesNanocapsulesIn vivoMaterials TestingmedicineAnimalsMyeloid CellsTissue DistributionMolecular Targeted TherapyMicrobubblesmedicine.diagnostic_testbusiness.industryMacrophages021001 nanoscience & nanotechnology3. Good healthCell biologyVisceraNanomedicine030104 developmental biologymedicine.anatomical_structureOrgan SpecificityMechanics of Materials2023 OA procedureLiposomesImmunologyDrug deliveryCeramics and CompositesMicrobubblesTargeted delivery0210 nano-technologybusinessBiomaterials
researchProduct

NLRP3 Inflammasome Biomarker-Could Be the New Tool for Improved Cardiometabolic Syndrome Outcome.

2020

Metabolomics, the research area studying chemical processes involving metabolites, finds its utility in inflammasome biomarker discovery, thus representing a novel approach for cardiometabolic syndrome pathogeny acknowledgements. Metabolite biomarkers discovery is expected to improve the disease evolution and outcome. The activation of abundantly expressed NLRP3 inflammasome represents the background process of the diabetes mellitus disturbances like hyperglycemia and insulin resistance, as well as for myocardial cell death and fibrosis, all of them being features characteristic for cardiometabolic syndrome. Many molecules like troponins, brain natriuretic protein (BNP), ST2/IL-33, C-reacti…

0301 basic medicineBiomarkers Cardiometabolic syndrome Inflammasome Metabolomics NLRP3 inflammasome Outcome Targeted therapyMyocarditisEndocrinology Diabetes and Metabolismmedicine.medical_treatmentReviewBioinformaticsBiochemistryTargeted therapy03 medical and health sciences0302 clinical medicineInsulin resistanceinflammasomeDiabetes mellitusmedicineMyocardial infarctionBiomarker discoveryMolecular Biologybusiness.industrybiomarkersInflammasomemedicine.diseasetargeted therapymetabolomicsNLRP3 inflammasome030104 developmental biology030220 oncology & carcinogenesisoutcomeBiomarker (medicine)cardiometabolic syndromebusinessmedicine.drugMetabolites
researchProduct

Skin-derived mesenchymal stem cells as quantum dot vehicles to tumors

2017

Dominyka Dapkute,1,2 Simona Steponkiene,1 Danute Bulotiene,1 Liga Saulite,3 Una Riekstina,3 Ricardas Rotomskis1,4 1Biomedical Physics Laboratory, National Cancer Institute, Vilnius, Lithuania; 2Institute of Biosciences, Vilnius University, Vilnius, Lithuania; 3Faculty of Medicine, University of Latvia, Riga, Latvia; 4Biophotonics Group of Laser Research Center, Faculty of Physics, Vilnius University, Vilnius, Lithuania Purpose: Cell-mediated delivery of nanoparticles is emerging as a new method of cancer diagnostics and treatment. Due to their inherent regenerative properties, adult mesenchymal stem cells (MSCs) are naturally attracted to wounds and sites of inflammation, as well as tumors.…

0301 basic medicineBiophysicsPharmaceutical ScienceConnective tissueBioengineeringBreast Neoplasmsquantum dotsMice SCIDFlow cytometryBiomaterialsCell therapy03 medical and health sciencesIn vivoCell MovementInternational Journal of NanomedicineCell Line TumorDrug DiscoverymedicineAnimalsHumansViability assayParticle SizeCytotoxicityCell ShapeSkinOriginal Researchmesenchymal stem cellsMigration Assaymedicine.diagnostic_testCell DeathChemistryOrganic ChemistryMesenchymal stem cellGeneral MedicineDynamic Light ScatteringEndocytosis030104 developmental biologymedicine.anatomical_structureimmunodeficient miceCancer researchNanoparticlesFemaletumor tropismtumor-specific deliveryInternational Journal of Nanomedicine
researchProduct

Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease

2016

AbstractWe have reviewed the effects of angiotensin II type 1 receptor antagonists (ARBs) in various animal models of hypertension, atherosclerosis, cardiac function, hypertrophy and fibrosis, glucose and lipid metabolism, and renal function and morphology. Those of azilsartan and telmisartan have been included comprehensively whereas those of other ARBs have been included systematically but without intention of completeness. ARBs as a class lower blood pressure in established hypertension and prevent hypertension development in all applicable animal models except those with a markedly suppressed renin–angiotensin system; blood pressure lowering even persists for a considerable time after d…

0301 basic medicineBlood Pressure030204 cardiovascular system & hematologyKidneyurologic and male genital diseasesBenzoatesAnimals Genetically ModifiedRenin-Angiotensin SystemGene Knockout Techniques0302 clinical medicineAzilsartanPharmacology (medical)TelmisartanOxadiazolesKidneybiologyStrokemedicine.anatomical_structureCardiovascular DiseasesHypertensionDrug Therapy Combinationmedicine.drugmedicine.medical_specialty03 medical and health sciencesMetabolic DiseasesCulture TechniquesInternal medicineRenin–angiotensin systemmedicineAnimalsHumansAntihypertensive AgentsPharmacologyAngiotensin II receptor type 1business.industryAngiotensin-converting enzymeAtherosclerosisLipid Metabolismmedicine.diseaseDisease Models AnimalGlucose030104 developmental biologyBlood pressureEndocrinologyPathophysiology of hypertensionbiology.proteinBenzimidazolesEndothelium VascularTelmisartanbusinessAngiotensin II Type 1 Receptor BlockersPharmacology & Therapeutics
researchProduct